Pharma & Biotech
The company acquired the shares through the conversion of unsecured debentures valued at $1.6 million
08.45 Fri 03 Jul 2020
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC.